1 / 19

Medical treatment of GERD is flawed :

Other treatments for GERD… Lee L Swanstrom MD, FACS Division of Minimally Invasive Surgery Legacy Health System Portland, OR. Medical treatment of GERD is flawed :. It is palliative only It doesn’t always work It doesn’t stop reflux It doesn’t alter the progression of Barrett’s to cancer

rigg
Download Presentation

Medical treatment of GERD is flawed :

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Other treatments for GERD…Lee L Swanstrom MD, FACSDivision of Minimally Invasive SurgeryLegacy Health SystemPortland, OR

  2. Medical treatment of GERD isflawed: • It is palliative only • It doesn’t always work • It doesn’t stop reflux • It doesn’t alter the progression of Barrett’s to cancer • It is expensive

  3. PPI-associated Complications Increase Over Time 10 Increased renal failure 8 Years on PPI therapy Increase of osteoporosis-associated fractures 7 5 Increased risk of hip fracture 7 4x the risk of gastric polyps 6 1 Increased risk of acute coronary syndrome when used with Plavix 1 Increased gallbladder motility 2 Increased bacterial gastroenteritis 3 Increased risk of Clostridium difficile colitis4 Decreased innate immunity 5 References 1 Ho et al. JAMA 2009; 20:1364-7. 2Cahan et al. Surg Endosc 2006; 20:1364-7. 3Garcia Rodriguez et al. Clin Gastroenterol Hepatol 2007; 5:1418-23. 4 Cadle et al. Am J Health Pharm 2007; 64:2359-2363.5Alkim et al. Dig Dis Sci 2008; 53:347-51.6Jalving et al. Aliment Pharmacol Ther 2006; 24:1341-8. 7Targownik et al. CMAJ 2008;179:319-26. 8Geevasinga et al. Clin Gastroenterol Hepatol 2006; 4:597-4.

  4. The problem with laparoscopic fundoplication… • Can be dangerous • Expensive ($13,500 at Legacy) • Side effects can outweigh benefits for early or mild disease • Not enough surgeons, ORs, time or energy to do lap Nissen on everyone

  5. Other options? • Gastric bypass • Endoluminal treatments • Gastric emptying • Laparoscopic Prosthesis

  6. Roux-en-Y Gastric Bypass • Most frequently performed bariatric procedure in the US • First done in 1967 • Some technical modifications since (stomach is cut) • Laparoscopically since 1993 • 60 –80% loss EBW • 75 – 80% effective control of reflux

  7. Endoluminal antireflux surgery: • Radiofrequency ‘scarring’ of the LES (STRETTA) • FDA approved 2/20/00 • Bard Sewing machine “endoplication” (Endocynch) • FDA approved 2/20/00 • Endoscopic intramuscular injections (Enteryxx) • Approved under PMA 6/03 • Transgastric / endoscopic repair (N-do) • National trials 9/03

  8. Nissen Esophafix (Endogastric Solutions) “World's First Endoluminal Fundoplication” Brussels team performs world's first endoluminal fundoplication (100% trans-oral incision-less) with clinical aim of curing gastroesophageal reflux disease (GERD).

  9. TIF Highlights • TIF has been used in eight unbiased clinical studies • Those clinical studies demonstrate that: • TIF is safe • TIF restores the GE valve anatomy and function • Results have been proven measuring: • Symptoms and quality of life • Use of PPIs • Impedance • pH-metry • Manometry • TIF2 improves on TIF1 • TIF is more effective than EndoCinch or Plicator • Additional clinical studies on the TIF Procedure are underway

  10. 10 Clinical Studies = 6 Completed + 4 In Progress Study (n) Available Data (n) Study Status Published TIF1: -Feasibility (19) 2 yrs (14) Completed Yes - Multicenter (86) 2 yrs (51) 3-yr in progress No - Redo (15) 6 mo (15) Completed No - Registry Fraser (20) 7 mo (20) Completed No - Registry Bouvy (38) 10 mo (38) Completed No TIF2: -Feasibility (10) 6 mo (10) Completed Yes - Randomized vs. PPIs (120) 6 mo (14) Enrolling n/a - Feasibility in children (14) 3 mo (14) Completed n/a - RCT vs. Sham (60) n/a EC review n/a - RCT vs. LNF in children (300)n/a EC review n/a RCT –randomized controlled trial

  11. Current strategy Chronic GERD symptoms Comprehensive evaluation [EGD, 24 hr pH, motility] Severe disease High DeMeester, esophagitis, Barrett’s, stricture, etc Mild disease Laparoscopic ARS Endoscopic ARS Breakthrough reflux post lap ARS

  12. LINX™ Reflux Management System Reinforces the LES restoring the barrier function Expands during swallow allowing food to enter stomach Highest Magnetic Resistance Lowest Magnetic Resistance

  13. LINX™ Design • Device Design • Titanium beads with magnetic cores • Linked together by titanium wires • Links limit expansion distance between beads • Resists sphincter relaxation while allowing normal physiological function (swallowing, belching, etc) • Mechanism of Action: Increased yield pressure of LES

  14. Barium Swallow: 1 Day Post-Op

  15. Dissect Size Place Secure LINX™ Procedure

  16. Healing Response: Porcine Explant (4 mo)

  17. Clinical Outcomes - Feasibility1 pH Normalization 79% No PPI Use 89% Median HRQL Reduction 96% 87% Reduction 1 – Bonavina, J Gastrointetinal Surg. 2008

  18. Pivotal Trial • Prospective, multi-center, single-arm study • Patient as their own control • N=100 subjects • Target Indication - subjects diagnosed with pathologic GERD as defined by abnormal pH scores and incomplete clinical response from medical therapy • Primary endpoint • Normalized or >50% reduction in acid exposure @ 1 year • Secondary Endpoints • >50% reduction in GERD HRQL @ 1 year • >50% reduction in PPI use @ 1 year

  19. Conclusions: • Reflux is a disease – it presents in a continuum of symptoms and causes. It varies with individuals • Treatments must be individualized to the patient’s psychology and physiology

More Related